An integrated rapid nucleic acid detection assay based on recombinant polymerase amplification for SARS-CoV-2

Virol Sin. 2022 Feb;37(1):138-141. doi: 10.1016/j.virs.2022.01.006. Epub 2022 Jan 13.

¹ Department of Virology, Beijing Institute of Microbiology and Epidemiology, AMMS, Beijing 100071, China; State Key Laboratory of Pathogen and Biosecurity, AMMS, Beijing 100071, China; Beijing University of Chemical Technology, Beijing 100029, China.
² Technology Center of Erenhot Customs, Erenhot 011100, China.
³ Department of Virology, Beijing Institute of Microbiology and Epidemiology, AMMS, Beijing 100071, China; State Key Laboratory of Pathogen and Biosecurity, AMMS, Beijing 100071, China.
⁴ Lifereal Biotech. Inc., Hangzhou 311100, China.
⁵ State Key Laboratory of Pathogen and Biosecurity, AMMS, Beijing 100071, China.
⁶ Department of Virology, Beijing Institute of Microbiology and Epidemiology, AMMS, Beijing 100071, China; State Key Laboratory of Pathogen and Biosecurity, AMMS, Beijing 100071, China; Anhui Medical University, Hefei 230032, China.
⁷ Department of Virology, Beijing Institute of Microbiology and Epidemiology, AMMS, Beijing 100071, China; State Key Laboratory of Pathogen and Biosecurity, AMMS, Beijing 100071, China; Anhui Medical University, Hefei 230032, China. Electronic address: jiangtao@bmi.ac.cn.
⁸ Department of Virology, Beijing Institute of Microbiology and Epidemiology, AMMS, Beijing 100071, China; State Key Laboratory of Pathogen and Biosecurity, AMMS, Beijing 100071, China; Beijing University of Chemical Technology, Beijing 100029, China. Electronic address: kangxiaoping@163.com.

Abstract

•
I-RPA was developed by combining sample treatment and RPA detection in a single sealed cartridge.
•
No cross reaction was found in respiratory tract-associated viruses.
•
The low limit of detection was 35 copies/reaction.
•
This I-RPA assay is suitable for detection and monitoring of SARS-CoV-2 in the field.